Whitehawk Therapeutics (NASDAQ:WHWK) Posts Earnings Results, Beats Expectations By $0.04 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) posted its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04, FiscalAI reports.

Whitehawk Therapeutics Trading Down 5.1%

WHWK opened at $3.94 on Friday. The stock’s fifty day simple moving average is $3.75 and its 200 day simple moving average is $2.96. Whitehawk Therapeutics has a 1-year low of $1.55 and a 1-year high of $4.48. The stock has a market cap of $194.75 million, a PE ratio of 8.38 and a beta of 0.70.

Insider Activity

In other Whitehawk Therapeutics news, insider Bryan Ball sold 92,460 shares of the business’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the sale, the insider owned 397,106 shares of the company’s stock, valued at $1,445,465.84. The trade was a 18.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Scott M. Giacobello sold 141,600 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $4.13, for a total transaction of $584,808.00. Following the transaction, the chief financial officer directly owned 295,224 shares in the company, valued at $1,219,275.12. This represents a 32.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 705,358 shares of company stock valued at $2,584,564 over the last ninety days. 49.90% of the stock is currently owned by company insiders.

Institutional Trading of Whitehawk Therapeutics

Several large investors have recently modified their holdings of the stock. Quadrature Capital Ltd bought a new position in shares of Whitehawk Therapeutics in the fourth quarter worth $28,000. ABG Innovation Capital Partners III GP Ltd bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP bought a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Squarepoint Ops LLC bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $159,000. Finally, Marshall Wace LLP bought a new stake in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Oppenheimer began coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Citizens Jmp assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price for the company. Finally, Citigroup started coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.